8 citations
,
November 2024 in “EMBO Molecular Medicine” Targeting JAK-STAT1 can reduce inflammation and promote hair growth in conditions linked to EGFR deficiency.
June 2026 in “Open Access Research Journal of Biology and Pharmacy” Bedaquiline, Telmisartan, Diosmin, Azelastine, and Adapalene may be effective treatments for onchocerciasis.
252 citations
,
November 1995 in “The EMBO Journal” Blocking EGFR in mice causes hair loss and skin changes.
May 2019 in “CINECA IRIS Institutial Research Information System (University of Genoa)” MITF+ melanoma patients are more likely to have multiple melanomas and unique skin patterns.
November 2025 in “The Journal of Immunology” The S1PR 1&4 modulator may effectively treat alopecia areata by reducing hair loss and immune cell activity.
October 2023 in “Frontiers in Pharmacology” Research on HIV-1 capsid inhibitors has progressed significantly, with the U.S. leading in contributions.
5 citations
,
March 2019 in “Journal of lipid research” New probes were created to effectively measure specific enzymes involved in fat metabolism, which could help develop new drugs.
October 2022 in “Journal of Armed Forces Medical College, Bangladesh” Tofacitinib is effective and safe for treating alopecia areata.
13 citations
,
April 2019 in “iScience” EGFR helps control how hair grows and forms without needing p53 protein.
2 citations
,
January 2025 in “Journal of Nanobiotechnology” A new engineered treatment shows promise in curing heart fibrosis.
12 citations
,
May 2019 in “Molecular Medicine Reports” Forsythiaside A helps reduce brain damage from lack of blood flow by activating certain protective pathways.
1 citations
,
January 2014 The F9 formulation of Finasteride tablets, using Eudragit, successfully controlled drug release.
December 2024 in “Frontiers in Pediatrics” Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.
84 citations
,
August 2023 in “Drugs” Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
52 citations
,
September 2014 in “Nature medicine” JAK inhibitors might help treat alopecia areata.
New pyridine compounds effectively inhibit GSK3, a diabetes treatment target.
May 2024 in “Journal of cosmetic dermatology” Tofacitinib is an effective and safe treatment for alopecia areata.
36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
March 2005 in “Inpharma Weekly” China approved Sinovac's flu vaccine, Japan approved RiUP for female hair loss, and Nippon Kayaku's three cancer drugs.
January 1994 in “European Journal of Cancer” The European School of Oncology organized various educational events in 1994, highlighting important cancer research findings.
October 2021 in “Revista Medicina Cutánea Ibero-Latino-Americana” PRIDE syndrome helps identify skin side effects from EGFR inhibitors like erlotinib.
29 citations
,
December 2022 in “Journal of Nanobiotechnology” Stem cell vesicles reduced eczema symptoms in mice safely.
61 citations
,
March 1990 in “Clinical pharmacology and therapeutics/Clinical pharmacology & therapeutics” Albendazole treatment for echinococcosis can cause serious side effects and requires close monitoring.
August 2024 in “Clinical Cosmetic and Investigational Dermatology” Ixekizumab effectively treated severe psoriasis and hair loss in a patient.
40 citations
,
March 1984 in “Acta dermato-venereologica” Etretinate has only moderate effects on localized scleroderma and lichen sclerosus.
79 citations
,
September 2018 in “Dermatologic therapy” Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
20 citations
,
December 2021 in “Journal of the American Academy of Dermatology” Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
4 citations
,
February 2019 in “Revista da Associação Médica Brasileira” FOLFOX6 chemotherapy effectively reduces VEGF levels and improves quality of life in advanced colorectal cancer patients.
2-Hydroxy-1,4-naphthoquinone is a strong 5α-reductase inhibitor.